Pharmaceuticals, Biotechnology and Life Sciences
REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who…
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to…
Extended Duration Formulation Ensures Cats Receive Broad-Spectrum Parasite Coverage in One Topical Application MADISON, N.J.–(BUSINESS WIRE)–$MRK #AnimalHealth–Merck Animal Health, a…
DUBLIN–(BUSINESS WIRE)–The “Osphena – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Osphena – Drug Insight, 2019 highlights…
FETROJA is the first approved antibiotic that functions as a siderophore FETROJA binds to free iron to gain additional cell…
FDA Accepts New Drug Application for Veverimer Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc.…
GUILFORD, Conn.–(BUSINESS WIRE)–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™…
– New findings in human sensory neurons highlight role of IL-13 in amplifying itch and lebrikizumab’s role in inhibiting itch…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug…
– Conference call and webcast to be hosted today at 4:30pm EDT – VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:…